This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Abbott Laboratories.
Costs (2011 values), which were modelled from the perspective of a US third-party payer, included those associated with antiretroviral drugs, non-antiretroviral drugs, opportunistic infection prophylaxis, routine medical care, and treatment of AIDS-related events and side effects.
Reference
Simpson KN, et al. Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States. PharmacoEconomics : 26 Apr 2013. Available from: URL: http://dx.doi.org/10.1007/s40273-013-0048-3
Rights and permissions
About this article
Cite this article
Lopinavir/ritonavir reduces costs of ART in HIV. PharmacoEcon Outcomes News 678, 7 (2013). https://doi.org/10.1007/s40274-013-0396-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0396-4